Allos

Allos is a California, US-based provider of an artificial intelligence platform designed for pharmaceutical manufacturing, enhancing therapeutic success through simulation technologies. Allos focuses on delivering AI solutions for pharmaceutical manufacturing. Founded in 2024, the company has engaged in 1 deal to date, with the most recent funding round on December 2025. In this Seed round, Allos raised USD 5.

000 mn led by Oxford Sciences Enterprises, with participation from Berkeley SkyDeck Fund and Habico Invest. The total amount raised by the company is USD 5. 000 mn. Allos specializes in providing a comprehensive artificial intelligence platform tailored for pharmaceutical manufacturing, focusing on enhancing therapeutic success through innovative simulation technologies.

The platform utilizes causal intelligence to model interventions and their outcomes before actual experiments, ensuring a well-defined operating window. Key offerings include simulation-led Design of Experiments (DoEs), robust scale-up methodologies, and data-driven tech transfer solutions, all aimed at minimizing risk and accelerating the drug development lifecycle. The company serves a diverse client base that includes pharmaceutical companies and biotechnology firms across North America and Europe, who rely on Allos's capabilities to achieve a higher probability of first-pass success in clinical trials. The platform's practical applications span from formulation development to clinical proof, ultimately improving patient outcomes by delivering precise dosages consistently.

Allos generates revenue through a subscription-based model that facilitates ongoing access to its AI platform and services. Clients engage in long-term partnerships with the company, leveraging its advanced tools for various phases of drug development, including formulation development, scale-up, and tech transfer. This structured transaction framework allows clients to integrate Allos's offerings into their workflows, enhancing decision-making processes and reducing experimental failures. Specific pricing plans are designed to cater to the unique needs of each client, with distinct tiers reflecting the complexity of services utilized.

By focusing on delivering high-value insights and operational efficiency, Allos secures its position within the competitive landscape of pharmaceutical manufacturing support services. In December 2025, Allos raised USD 5. 00 mn in Seed funding led by Oxford Sciences Enterprises, with participation from Habico Invest. The company plans to utilize this funding to expand its formulation development and data science capabilities.

Allos is targeting growth into new geographic regions and markets, focusing specifically on Europe and Asia by 2027. Additionally, Allos is currently designing new products aimed at improving AI-driven solutions for drug development, with anticipated launches expected in late 2026.